BRIEF-AstraZeneca announces results from SYMBICORT study By: Reuters: Company News August 31, 2016 at 17:07 PM EDT * SYMBICORT demonstrated comparable risk of serious asthma-related events and lower risk of asthma exacerbations compared to Budesonide alone Read More >> Related Stocks: Astrazeneca Plc ADR